StreetInsider.com News Articles

Seraxis names ex-FDA officer as CMO ahead of Sernova merger

Mon, 19 Oct 2026 07:00:56 -0400

Seraxis Holdings, Inc. and Sernova Biotherapeutics Inc. (TSX: SVA) (OTC: SEOVF) announced the appointment of Patricia Beaston, MD, PhD, as Chief Medical Officer of Seraxis. Upon completion of the companies' proposed merger to form BetaNova Biotherapeutics, Inc., Dr. Beaston is expected to hold the same role at the combined company.

Dr. Beaston spent 24 years as a Medical Officer at the U.S. Food and Drug Administration, working across three agency centers: the Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, and most recently the Center for Biologics Evaluation and Research, where her work included islet cell

Seraxis names ex-FDA officer as CMO ahead of Sernova merger

Mon, 19 Oct 2026 07:00:56 -0400

Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics

Mon, 19 Oct 2026 07:00:00 -0400

GERMANTOWN, Md. and TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Seraxis Holdings, Inc. (“Seraxis”) and Sernova Biotherapeutics Inc. (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) today announced the appointment of Patricia Beaston, MD, PhD, as Chief Medical Officer (CMO) of Seraxis. Upon completion of the companies' proposed merger to form BetaNova Biotherapeutics, Inc. (“BetaNova”), Dr. Beaston will assume the same role at the combined company.

Dr. Beaston brings 24 years of experience as a Medical Officer at the U.S. Food and Drug Administration (FDA), with expertise spanning endocrine therapeutics, medical devices, islet cell transplantation, immune

Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics

Mon, 19 Oct 2026 07:00:00 -0400

Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics

Mon, 19 Oct 2026 07:00:00 -0400

Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics

Mon, 19 Oct 2026 07:00:00 -0400

Sernova and Seraxis close $11.2M financing ahead of merger

Mon, 05 Oct 2026 07:00:42 -0400

Sernova Biotherapeutics Inc. (TSX: SVA, OTC: SEOVF) and Seraxis Holdings, Inc. have closed a US$11.2 million non-brokered convertible note financing into Seraxis, according to a press release. The financing, which exceeded the initially targeted US$10 million, is connected to the companies' proposed merger to form BetaNova Biotherapeutics, Inc.

Participants in the financing include company insiders, management from both Sernova and Seraxis, existing shareholders, and new investors.

Proceeds are intended to fund several activities, including the cGMP manufacturing of SR-02, an allogeneic stem cell-derived pancreatic islet cell therapy for type 1 diabetes (T1D). Patient enrollment for a Phase 1/2 clinical trial is planned

Sernova and Seraxis close $11.2M financing ahead of merger

Mon, 05 Oct 2026 07:00:42 -0400

Participants in the financing include company insiders, management from both Sernova and Seraxis, existing shareholders, and new investors.

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Mon, 05 Oct 2026 07:00:00 -0400

TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. (“Seraxis”) today announced the closing of the previously announced targeted US$10 million non-brokered convertible note financing in connection with their proposed merger (the "Merger") to form BetaNova Biotherapeutics, Inc. (“BetaNova”).

The US$11.2 million financing into Seraxis includes participation from insiders, Dr. Steven Sangha / Arlo Investments, Sernova management; Jonathan Rigby CEO, James Parsons CFO, Marylyn Rigby CCO, and David Burke VP IR, as well as Seraxis management; Will Rust Ph.D. CEO,

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Mon, 05 Oct 2026 07:00:00 -0400

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Mon, 05 Oct 2026 07:00:00 -0400

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Mon, 05 Oct 2026 07:00:00 -0400

Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Fri, 25 Sep 2026 07:00:00 -0400

TORONTO and GERMANTOWN, Md., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a clinical-stage regenerative medicine company focused on developing cell therapies with the goal of delivering a functional cure for type 1 diabetes (T1D), today announced Sernova and Seraxis Holdings, Inc. (“Seraxis”) will participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, October 1, at 1:30 p.m. Eastern Time.

Jonathan Rigby, President and CEO of Sernova, will be joined by Will Rust, Ph.D., President and CEO of Seraxis, for a joint presentation and fireside-style

Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Fri, 25 Sep 2026 07:00:00 -0400

Jonathan Rigby, President and CEO of Sernova, will be joined by Will Rust, Ph.D., President and CEO of Seraxis, for a joint presentation and fireside-style

Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Fri, 25 Sep 2026 07:00:00 -0400

Jonathan Rigby, President and CEO of Sernova, will be joined by Will Rust, Ph.D., President and CEO of Seraxis, for a joint presentation and fireside-style

Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Fri, 25 Sep 2026 07:00:00 -0400

Jonathan Rigby, President and CEO of Sernova, will be joined by Will Rust, Ph.D., President and CEO of Seraxis, for a joint presentation and fireside-style

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Thu, 10 Sep 2026 07:00:00 -0400

TORONTO and GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced it will be participating in the upcoming H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026, in New York. Jonathan Rigby, Sernova’s President and CEO, will be joined by Will Rust, Ph.D., President and CEO of Seraxis Holdings, Inc. ("Seraxis") and a joint, in-person presentation will be made on Wednesday 16th September

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Thu, 10 Sep 2026 07:00:00 -0400

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Thu, 10 Sep 2026 07:00:00 -0400

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Thu, 10 Sep 2026 07:00:00 -0400

Sernova and Seraxis agree to merge, forming BetaNova Biosciences

Tue, 08 Sep 2026 07:01:41 -0400

Sernova Biotherapeutics Inc. (TSX: SVA) (OTC: SEOVF) and Seraxis Holdings, Inc. have entered into a definitive agreement to merge and form a new company called BetaNova Biotherapeutics, Inc., focused on type 1 diabetes (T1D) islet cell replacement therapy.

Under the terms of the agreement, shareholders of both Sernova and Seraxis will each own approximately 50% of BetaNova upon completion of the merger. The combined company will be headquartered in Germantown, Maryland, and will incorporate Sernova's Cell Pouch Bio-hybrid Organ with Seraxis' stem cell-derived pancreatic islet cells and in-house cGMP manufacturing capabilities.

A $10 million non-brokered convertible note financing has been secured from

Sernova and Seraxis agree to merge, forming BetaNova Biosciences

Tue, 08 Sep 2026 07:01:41 -0400

A $10 million non-brokered convertible note financing has been secured from

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Wed, 17 Jun 2026 07:00:00 -0400

Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating